Research Analysts Issue Forecasts for TBPH FY2024 Earnings

Theravance Biopharma, Inc. (NASDAQ:TBPH) – Analysts at HC Wainwright issued their FY2024 earnings estimates for shares of Theravance Biopharma in a report released on Tuesday, February 25th. HC Wainwright analyst D. Tsao forecasts that the biopharmaceutical company will post earnings per share of ($1.01) for the year. HC Wainwright currently has a “Buy” rating and a $15.00 price objective on the stock. The consensus estimate for Theravance Biopharma’s current full-year earnings is ($1.09) per share. HC Wainwright also issued estimates for Theravance Biopharma’s Q4 2024 earnings at ($0.17) EPS, FY2025 earnings at ($0.69) EPS, FY2026 earnings at ($0.42) EPS and FY2027 earnings at ($0.43) EPS.

Theravance Biopharma (NASDAQ:TBPH) last announced its quarterly earnings results on Wednesday, February 26th. The biopharmaceutical company reported ($0.31) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.26). Theravance Biopharma had a negative net margin of 78.18% and a negative return on equity of 24.79%. The business had revenue of $18.75 million for the quarter, compared to analyst estimates of $29.90 million.

Theravance Biopharma Trading Up 2.1 %

NASDAQ:TBPH opened at $9.27 on Thursday. The firm’s fifty day simple moving average is $9.34 and its 200 day simple moving average is $8.92. Theravance Biopharma has a twelve month low of $7.44 and a twelve month high of $10.90. The firm has a market capitalization of $455.84 million, a price-to-earnings ratio of -9.18 and a beta of 0.21.

Insiders Place Their Bets

In other news, SVP Rhonda Farnum sold 4,000 shares of the stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $9.00, for a total value of $36,000.00. Following the completion of the sale, the senior vice president now owns 309,565 shares in the company, valued at approximately $2,786,085. This trade represents a 1.28 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 6.90% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Theravance Biopharma

Institutional investors and hedge funds have recently bought and sold shares of the stock. Newtyn Management LLC lifted its position in shares of Theravance Biopharma by 5.7% during the fourth quarter. Newtyn Management LLC now owns 4,757,403 shares of the biopharmaceutical company’s stock worth $44,767,000 after purchasing an additional 258,337 shares in the last quarter. BNP Paribas Financial Markets increased its stake in Theravance Biopharma by 88.9% during the 3rd quarter. BNP Paribas Financial Markets now owns 305,480 shares of the biopharmaceutical company’s stock worth $2,462,000 after buying an additional 143,781 shares during the period. Algert Global LLC acquired a new position in Theravance Biopharma in the 3rd quarter worth $851,000. Dimensional Fund Advisors LP boosted its position in Theravance Biopharma by 20.8% in the 4th quarter. Dimensional Fund Advisors LP now owns 553,713 shares of the biopharmaceutical company’s stock valued at $5,211,000 after buying an additional 95,304 shares during the last quarter. Finally, Millennium Management LLC grew its stake in shares of Theravance Biopharma by 71.1% during the fourth quarter. Millennium Management LLC now owns 192,839 shares of the biopharmaceutical company’s stock valued at $1,815,000 after acquiring an additional 80,140 shares in the last quarter. Hedge funds and other institutional investors own 99.10% of the company’s stock.

About Theravance Biopharma

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.